Caveolin-1, GATA-3, and Ki67 expressions and their correlation with pathological findings in canine bladder urothelial carcinoma.
biomarker
cancer
dog
immunohistochemistry
neoplasia
Journal
Frontiers in veterinary science
ISSN: 2297-1769
Titre abrégé: Front Vet Sci
Pays: Switzerland
ID NLM: 101666658
Informations de publication
Date de publication:
2022
2022
Historique:
received:
04
07
2022
accepted:
20
09
2022
entrez:
27
10
2022
pubmed:
28
10
2022
medline:
28
10
2022
Statut:
epublish
Résumé
The bladder urothelial carcinoma (UC) represents ~2% of malignant neoplasms in dogs and is a therapeutic challenge in veterinary medicine. Although it is considered the most common bladder cancer in dogs, few previous studies have investigated different markers that correlate with clinical and pathological parameters. Therefore, this study aimed to evaluate Caveolin-1, GATA-3, and Ki67 immunostaining in canine UC samples to evaluate their correlations with histopathological variables. Thirty tumor samples were obtained, and Caveolin-1, GATA-3, and Ki67 expression was assessed by immunohistochemistry and associated with pathological factors by univariate and multivariate analyses. Among the histopathological findings, lymphatic invasion was identified in 53.33% of the tumors, and the mean mitotic count (MC) was 31.82 ± 26.26. Caveolin-1 showed mild-to-high cytoplasmic expression in neoplastic cells, whereas GATA-3 showed mild-to-high nuclear expression. The Ki67 expression revealed a mean of 24.14 ± 16.88% positive cells. In the univariate analysis, no association was found between each marker and the pathological findings. On the other hand, in multivariate analysis, we identified a positive correlation between GATA-3 and MC and a negative correlation between Caveolin-1 and MC. Moreover, lymphatic invasion was positively correlated with histological type and grade, and negatively correlated with MC. In addition, the histological type was positively correlated with the histological grade. Overall, our results indicate that Caveolin-1 and GATA-3 expression could be promising markers for bladder UC aggressiveness.
Identifiants
pubmed: 36299636
doi: 10.3389/fvets.2022.986269
pmc: PMC9589490
doi:
Types de publication
Journal Article
Langues
eng
Pagination
986269Informations de copyright
Copyright © 2022 Govoni, Pigoli, Brambilla, Ruiz Sueiro, Torres Neto, Laufer-Amorim, Gomes Quitzan, Grieco and Fonseca-Alves.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Am Vet Med Assoc. 1999 Dec 1;215(11):1629-34
pubmed: 14567425
Hum Pathol. 2019 Feb;84:275-282
pubmed: 30359638
J Comp Pathol. 1995 Aug;113(2):113-30
pubmed: 8543669
Front Vet Sci. 2020 Nov 16;7:558978
pubmed: 33304937
Am J Clin Pathol. 2003 Jul;120(1):93-100
pubmed: 12866378
BMJ Open. 2018 Apr 17;8(4):e019635
pubmed: 29666128
Acta Vet Scand. 2018 Oct 29;60(1):66
pubmed: 30373614
Eur Urol. 2017 Jan;71(1):96-108
pubmed: 27370177
Pathology. 2016 Oct;48(6):543-9
pubmed: 27594510
ILAR J. 2014;55(1):100-18
pubmed: 24936033
Indian J Surg Oncol. 2021 Apr;12(Suppl 1):72-78
pubmed: 33994731
Eur Urol Focus. 2019 Jan;5(1):97-103
pubmed: 28753840
Anticancer Res. 2011 Oct;31(10):3503-6
pubmed: 21965769
Tumour Biol. 2014 Apr;35(4):2989-95
pubmed: 24241960
J Cancer Res Clin Oncol. 2019 Jul;145(7):1709-1718
pubmed: 31030273
Int J Mol Sci. 2018 Aug 28;19(9):
pubmed: 30154342
Vet Pathol. 2011 Jan;48(1):41-53
pubmed: 21123859
Front Oncol. 2020 Jan 21;9:1493
pubmed: 32039002
Cancer. 2018 Jun 15;124(12):2507-2514
pubmed: 29624636
J Vet Med Sci. 2015 Jan;77(1):1-6
pubmed: 25223345
Open Vet J. 2021 Oct-Dec;11(4):535-543
pubmed: 35070848
Hum Pathol. 2014 Jul;45(7):1466-72
pubmed: 24745616
Nat Rev Urol. 2016 Aug;13(8):471-9
pubmed: 27431340
Urol Clin North Am. 1992 Aug;19(3):435-53
pubmed: 1636229
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Hum Pathol. 2012 Nov;43(11):2033-40
pubmed: 22607700
Indian J Pathol Microbiol. 2017 Oct-Dec;60(4):505-509
pubmed: 29323062
Curr Opin Genet Dev. 2002 Aug;12(4):416-22
pubmed: 12100886
Tumour Biol. 2014 Dec;35(12):12031-47
pubmed: 25192721
Pathol Res Pract. 2008;204(10):707-17
pubmed: 18572327
Genome Biol. 2004;5(3):214
pubmed: 15003112
Am J Surg Pathol. 2014 Jan;38(1):13-22
pubmed: 24145643
Vet Comp Oncol. 2016 Sep;14(3):263-9
pubmed: 24758385
J Vet Diagn Invest. 2018 Mar;30(2):263-267
pubmed: 29192554
Vet Pathol. 2007 May;44(3):335-41
pubmed: 17491075
Res Vet Sci. 2015 Oct;102:122-6
pubmed: 26412531